Q3 2020 Sales Performance

Progressing our innovative new medicines Building momentum with impactful programmes across the portfolio GSK '836 in chronic Hepatitis B • • • Programme in-licensed from lonis Pharmaceuticals in Q3 2019 Ph2a data presented at AASLD (Nov)1 HBsAg reduction seen in HBeAg positive and negative patients with 300mg dose Ph2b study started GSK '609 ICOS agonist in HNSCC • Demonstrated activity in both monotherapy and PD-1 combo Ph 2/3 gated studies INDUCE-3 and INDUCE-4 in HNSCC initiated gepotidacin in uUTIs and gonorrhoea • gsk UUTI and GC not addressed by new oral antibiotics in 20 years • ~40% of uUTI patients have antibiotic resistance infections² • • Emerging resistance to 1st line therapy for gonorrhea 3,4,5 Ph3 programme initiated to investigate gepo vs. ceftriaxone + azithromycin (GC) and gepo vs. nitrofurantoin (uUTI) Ph3 results expected 1H 2022 daprodustat in anaemia • Futility analysis performed Dec 2019 on CV outcome studies, which are continuing without modification Approved in Japan for anaemia due to chronic kidney disease • Design allows progression to pivotal if interim analysis positive Further POC data expected 2021 CVOT data expected 2H 2021 UUTIS = uncomplicated urinary tract infections; GC = urogenital gonorrhea; HNSCC = head and neck squamous cell carcinoma; POC = proof of concept; PMDA = Pharmaceuticals and Medicines Device Agency 1. Yuen MF et al. Phase 2a, randomized, double-blind, placebo-controlled study of an antisense inhibitor (ISIS 505358) in treatment-naïve chronic hepatitis B (CHB) patients: safety and antiviral efficacy. Poster presented at AASLD, The Liver Meeting, November 8-12, 2019, Boston. 2. World Health Organization STD Fact Sheet 2016: https://www.who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis) 3. Workowski KA, Berman SM, Douglas Jr. JM. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med. 2008;148(8):606-13 4. Antibiotic Resistance Threats in the United States. US CDC https://www.cdc.gov/drugresistance/biggest-threats.html 5. GSK US physician market research, 2019 59

View entire presentation